LEADER 03519oam 2200865zu 450 001 9910144725803321 005 20220809222036.0 010 $a0-470-51042-0 010 $a0-470-51041-2 035 $a(CKB)1000000000377338 035 $a(SSID)ssj0000354626 035 $a(PQKBManifestationID)11272620 035 $a(PQKBTitleCode)TC0000354626 035 $a(PQKBWorkID)10302389 035 $a(PQKB)10120943 035 $a(EXLCZ)991000000000377338 100 $a20160829d2007 uy 101 0 $aeng 181 $ctxt 182 $cc 183 $acr 200 10$aPharmacotherapy of bipolar disorders 210 31$a[Place of publication not identified]$cJohn Wiley & Sons Ltd$d2007 300 $aBibliographic Level Mode of Issuance: Monograph 311 $a0-470-05823-4 327 $aEpidemiology of bipolar disorders -- Classification of bipolar disorders -- How to define a mood stabilizer -- Lithium -- Carbamazepine -- Lamotrigine -- Topiramate -- Valproic acid -- The role of atypical or second generation antipsychotics -- Other medications used for bipolar disorders -- Medications that may potentially induce a depressive state -- Medications that may potentially induce a (hypo)manic syndrome -- Maintenance treatment : when should a long-term treatment be introduced -- Treatment of the depressive phase of bipolar disorders -- Treatment of bipolar II disorder -- Treatment of manic phases -- Treatment of rapid cycling -- Treatment of mixed states -- Combination treatments -- Bipolar disorders, pregnancy and breastfeeding -- Bipolar disorders in children and adolescents -- Bipolar disorders in geriatric patients. 606 $aManic-depressive illness$xChemotherapy 606 $aAntimanic Agents 606 $aBipolar Disorder 606 $aDrug Therapy 606 $aTranquilizing Agents 606 $aTherapeutics 606 $aAffective Disorders, Psychotic 606 $aPsychotropic Drugs 606 $aCentral Nervous System Depressants 606 $aMood Disorders 606 $aPhysiological Effects of Drugs 606 $aMental Disorders 606 $aCentral Nervous System Agents 606 $aPharmacologic Actions 606 $aTherapeutic Uses 606 $aChemical Actions and Uses 606 $aPsychiatric Disorders, Individual$2HILCC 606 $aPsychiatry$2HILCC 606 $aHealth & Biological Sciences$2HILCC 615 0$aManic-depressive illness$xChemotherapy 615 2$aAntimanic Agents 615 2$aBipolar Disorder 615 2$aDrug Therapy 615 2$aTranquilizing Agents 615 2$aTherapeutics 615 2$aAffective Disorders, Psychotic 615 2$aPsychotropic Drugs 615 2$aCentral Nervous System Depressants 615 2$aMood Disorders 615 2$aPhysiological Effects of Drugs 615 2$aMental Disorders 615 2$aCentral Nervous System Agents 615 2$aPharmacologic Actions 615 2$aTherapeutic Uses 615 2$aChemical Actions and Uses 615 7$aPsychiatric Disorders, Individual 615 7$aPsychiatry 615 7$aHealth & Biological Sciences 676 $a616.89/5061 700 $aAubry$b Jean-Michel$0946624 702 $aAubry$b Jean-Michel 702 $aSchaad$b Nicolas 702 $aFerrero$b François-P 702 $aFerrero$b Franðcois-P 801 0$bPQKB 906 $aBOOK 912 $a9910144725803321 996 $aPharmacotherapy of bipolar disorders$92138704 997 $aUNINA